AstraZeneca Provides Update on P-III (CAPItello-281) Study of Truqap Regimen in PTEN-Deficient mHSPC
Shots:
- The P-III (CAPItello-281) study is assessing the safety & efficacy of Truqap + abiraterone & ADT vs PBO + abiraterone & ADT for treating patients (n=1,012) with PTEN-deficient de novo mHSPC
- Study demonstrated a significantly improved rPFS (1EP) and a trend favoring improved OS, with further assessment underway (2EP); safety profile aligned with known data. Results will be highlighted at future conferences and shared with regulatory authorities
- Truqap is a FIC ATP-competitive inhibitor of AKT1/2/3 that is being studied under P-III studies for breast cancer (CAPItello-292) and prostate cancer (CAPItello-280, CAPItello-281) in addition to standard treatments
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Reports the CHMP’s Positive Opinion of Tagrisso (Osimertinib) for Treating Unresectable EGFR-Mutated Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
